De Pinte (BE)
{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~7 mi. (Gent, Belgium, +192 more cities)
facility
UZ Gent
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~7 mi. (Gent, Belgium, +176 more cities)
facility
Universitair Ziekenhuis Gent ( Site 2037), +1 more facility
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~7 mi. (Gent, Belgium, +147 more cities)
facility
AZ St Lucas ( Site 0349)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~7 mi. (Gent, Belgium, +130 more cities)
facility
UZ Gent ( Site 0101), +1 more facility
condition
Bladder Urothelial Carcinoma
drug
BCG solution, +1 more drug
drug type
immunotherapy
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~7 mi. (Gent, Belgium, +199 more cities)
facility
UZ Gent ( Site 0375)
condition
Hepatocellular Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~7 mi. (Gent, Belgium, +207 more cities)
facility
AZ Maria Middelares Gent ( Site 0700)
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~7 mi. (Gent, Belgium, +159 more cities)
facility
AZ Maria Middelares Gent ( Site 0353)
condition
Superficial Bladder Urothelial Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~7 mi. (Gent, Belgium, +163 more cities)
facility
AZ Maria Middelares Gent ( Site 0353)
condition
Bladder Urothelial Carcinoma
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types